Loading...
Loading...
Contributors:
Dataset URI:
10.3389/fsurg.2026.1898220.s002Background and objectiveBenign prostatic obstruction (BPO) is a common condition primarily affecting men over the age of 60. The associated lower urinary tract symptoms (LUTS) vary from mild to severe and are often pervasive, significantly impacting quality of life. There have been many pharmacological treatments developed to treat BPO. This review aims to assess the efficacy of different non-hormonal, pharmacological treatment options at alleviating the symptoms of BPO.MethodsA descriptive systematic review of studies published between January 2005 and March 2025 was conducted across MEDLINE, Cochrane, Web of Science and Scopus according to PRISMA guidance. Studies evaluating non-hormonal pharmacological therapies in adult men with BPO were included. Primary outcomes were IPSS, IPSS QoL, Qmax, and PVR. Secondary outcomes were adverse effects and rates of discontinuation. Treatment arms were grouped by pharmacological class, monotherapy and combination therapy, and arm-level outcomes were summarised descriptively without meta-analysis.Results42 studies involving 10,066 participants were included. 7,916 participants were allocated to receive the following treatments; a1-adrenergic receptor antagonists (a1-blockers) (n = 1,911), phosphodiesterase type 5 inhibitors (PDE5-i) (n = 4,579), combination of a1-blockers and PDE5-i (n = 1,206), and an antimuscarinic in combination therapy (n = 220). The use of a1-blockers, PDE5-i, the combination of a1-blockers and PDE5-i, and its use alongside antimuscarinics yielded reductions in IPSS. Improvements in Qmax were modest with monotherapy. Use of a1-blocker + PDE5-i combination therapy showing the greatest improvements across all primary outcome parameters.ConclusionIn contemporary trials, non-hormonal pharmacological therapies were associated with symptomatic improvement in men with LUTS secondary to BPO, with the largest numerical improvements in arms combining an a1-blocker with a PDE5-i. These unadjusted, descriptive observations do not establish comparative superiority. The evidence base remains limited by short follow-up and the near absence of progression endpoints; future trials should report long-term outcomes such as acute urinary retention and the need for surgery, and should stratify by patient characteristics such as storage symptoms, erectile dysfunction and prostate volume.
Keyword(s):
benign prostatic hyperplasia; LUTS (lower urinary tract symptoms); non-hormonal; pharmacology; prostate.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)